Commentary · 28 Jan 2022
CommentaryPublished 24 Jun 2021
Class Pharmacological Medicine
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Suitable models of Type 2 Diabetes Mellitus (T2DM) are being sought to investigate various treatment options. The neonatal streptozotocin (nSTZ) model has been explored and this study investigated the success and mortality rates of the nSTZ T2DM model. Following ethical approval by the University Hospital of the West Indies/University of the West Indies/Faculty of Medical Sciences Ethics Committee, two- and three-day old neonatal rat pups (n=66) were injected intraperitoneally with 60 mg/kg STZ (Sigma, France). Normal control pups (n=9) received equivalent volume of citrate buffer. Weaned animals were allowed free access to chow and water and kept at a constant light cycle of 12 hours on/12 hours off. Following an eight-hour fast, tail vein blood glucose was assessed weekly using Accu Chek Advantage glucometer (Roche Diagnostics, Germany). Oral glucose tolerance test was used to assess the type of diabetes in hyperglycaemic animals. Type 2 diabetes mellitus (T2DM) can be induced in neonatal rat pups using streptozotocin in various concentrations, and the model simulates the characteristics of T2DM well. This paper highlights the lengthy duration for development of T2DM in the neonatal model (up to 14 weeks) and its associated potential high mortality rate of up to 32.6 % (with range 0 to 100 %). It calls into question whether the nSTZ model in its current form is worthwhile, and points to greater impetus to perfect the technique of successful induction of T2DM with significantly lower mortality. Neonatal mortality occurred within 10 days of STZ injection and successful diabetes development occurred mostly between 8 and 10 weeks post-STZ at a rate of 40.9 % of the total number of pups injected with STZ (or 81.8 % of pups that survived STZ injection).
Keywords
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 24 Jun 2021
Class Pharmacological Medicine and Ecological Toxicology
Conference abstract · 1 Jun 2019
Clinical Pharmacy-2013 : Social pharmacology: Foundation for clinical pharmacy - Jose-Luis Alloza - The University of Alcala School of Medicine and Health Sciences
Article · 26 Jun 2024
Novel Therapeutics in Cardiovascular Pharmacology: Emerging Drug Classes and Mechanisms of Action
Short communication · 27 Oct 2023
Exploring the World of Pharmacology: An Overview of Drug Classes
More from this journal
The newest in Endocrinology & Diabetes Research.
Editorial · 31 Dec 2025
Beta-Cell Regeneration Therapies: Advancing Strategies to Restore Insulin Production in Diabetes Management
Editorial · 31 Dec 2025
Continuous Glucose Monitoring Analytics: Transforming Diabetes Management Through Data-Driven Insights
Editorial · 31 Dec 2025
Thyroid Dysfunction and Insulin Resistance: Interactions Between Thyroid Hormones and Glucose Metabolism in Metabolic Health
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEndocrinology & Diabetes Research
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Garsha McCalla”

